MM-121 is a fully human monoclonal antibody that targets ErbB3.
The trial is intended to assess the safety and pharmacokinetics of MM-121 when administered in combination with separate chemotherapy regimens.
The study sites in North America and the European Union are likely to participate in this trial.
Merrimack signed an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.